Published in BMJ on September 06, 1997
Not one academy but two. BMJ (1998) 0.75
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Adenosine 3',5'-monophosphate as the intracellular mediator of the action of adrenocorticotropic hormone on the adrenal cortex. J Biol Chem (1967) 3.03
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J (1969) 2.08
Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol (1971) 1.90
Misuse of temazepam. BMJ (1991) 1.82
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44
Proceedings: An isolated perfused rat brain--some histological and metabolic features. Clin Sci Mol Med (1974) 1.38
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol (1989) 1.35
Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35
Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage. Q J Med (1978) 1.34
Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. Clin Sci (Lond) (1985) 1.34
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol (1975) 1.31
Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes. J Neurol Neurosurg Psychiatry (1975) 1.28
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26
(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature (1976) 1.26
Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. Br J Clin Pharmacol (1979) 1.23
A sensitive radioenzymatic assay for adrenaline and noradrenaline in plasma. Br J Clin Pharmacol (1977) 1.17
The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer (1994) 1.15
A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]-dihydroergocryptine. J Auton Pharmacol (1983) 1.15
The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol (1974) 1.13
The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology (1975) 1.13
Psittacosis masquerading as rheumatic fever. Br Med J (1978) 1.12
Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology (1983) 1.12
The relationship between plasma catecholamines and severity of injury in man. J Trauma (1984) 1.11
Abnormal regulation of adenosine 3',5'-monophosphate and corticosterone formation in an adrenocortical carcinoma. J Clin Invest (1969) 1.11
Enhanced 5-hydroxytryptamine-mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. Psychopharmacology (Berl) (1979) 1.11
Enhancement of specific [3H]ouabain binding and ouabain sensitive 86rubidium influx in intact human lymphocytes by a dialysable factor in human and fetal calf serum. Clin Sci (Lond) (1987) 1.10
The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy. Br J Clin Pharmacol (1979) 1.10
Platelet aggregation and chlorpromazine therapy. Br J Clin Pharmacol (1978) 1.10
Plasma adrenaline and noradrenaline concentrations and dopamine-beta-hydroxylase activity in myocardial infarction with and without cardiogenic shock. Br Heart J (1979) 1.10
The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [3H]-ouabain binding to human lymphocytes after incubation for 3 days. Br J Clin Pharmacol (1986) 1.07
The contrasting actions of TRH and cycloheximide in altering the effects of centrally acting drugs: evidence for the non-involvement of dopamine sensitive adenylate cyclase. Neuropharmacology (1976) 1.05
Tryptophan hydroxylation in brain. Biochem Biophys Res Commun (1964) 1.04
The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects. Biochem J (1972) 1.04
Evidence for the presence of a vasoactive substance (possibly involved in the aetiology of cerebral arterial spasm) in cerebrospinal fluid from patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry (1976) 1.04
The biosynthesis of 5-hydroxytryptamine in brain. Biochem J (1967) 1.03
Altered distribution of digoxin in renal failure--a cause of digoxin toxicity? Br J Clin Pharmacol (1976) 1.03
The carcinoid syndrome. Am J Cardiol (1968) 1.00
TRH potentiates behavioural changes following increased brain 5-hydroxytryptamine accumulation in rats. Nature (1974) 0.99
Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med (1979) 0.98
Cation transport abnormalities in vivo in untreated essential hypertension. Clin Sci (Lond) (1986) 0.98
A method for the study of cation transport in vivo: effects of digoxin administration and of chronic renal failure on the disposition of an oral load of rubidium chloride. Clin Sci (Lond) (1984) 0.97
The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. Br J Clin Pharmacol (1981) 0.97
Somatostatin, gastrointestinal peptides, and the carcinoid syndrome. Gut (1981) 0.96
Changes in platelet alpha 2-adrenoceptor binding post partum: possible relation to maternity blues. Lancet (1983) 0.96
BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology (1993) 0.96
Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694). Brain Res (1991) 0.95
Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution. Br J Clin Pharmacol (1977) 0.95
In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anaesthetized rat using microdialysis: changes in relation to 5-hydroxytryptaminergic neuronal activity. J Neurochem (1989) 0.94
Evidence for an altered mode of action of the sodium-lithium countertransporter in vivo in patients with untreated essential hypertension. J Hypertens (1993) 0.94
Monitoring digoxin therapy. The use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity. Q J Med (1978) 0.94
Single and repeated administration of neuroleptic drugs to rats: effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and L-tryptophan or L-Dopa. Psychopharmacology (Berl) (1976) 0.93
Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. Br J Clin Pharmacol (1979) 0.93
Effect of oral contraceptives on platelet noradrenaline and5-hydroxytryptamine receptors and aggregation. Lancet (1979) 0.93
Repeated electroconvulsive shock extends the duration of enhanced gene expression for BDNF in rat brain compared with a single administration. Brain Res Mol Brain Res (1998) 0.92
The binding characteristics of [3H]-dihydroergocryptine on intact human platelets. Br J Pharmacol (1982) 0.92
Tryptophan transport across the synaptosomal membrane. J Neurochem (1970) 0.91
Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br J Pharmacol (1990) 0.91
Evidence for presynaptic 5-hydroxytryptamine3 recognition sites on vagal afferent terminals in the brainstem of the ferret. Neuroscience (1990) 0.91
Treatment of the carcinoid syndrome by local removal of hepatic metastases. Proc R Soc Med (1972) 0.91
The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology (Berl) (1990) 0.90
Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. Br J Pharmacol (1989) 0.89
The biosynthesis of 5-hydroxytryptamine in carcinoid tumours and intestine. Clin Sci (1967) 0.89
Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties. Br J Clin Pharmacol (1975) 0.89
Pharmacological blockade of carcinoid flushing provoked by catecholamines and alcohol. Lancet (1969) 0.89
The effects of iron deficiency on brain biogenic monoamine biochemistry and function in rats. Neuropharmacology (1980) 0.88
Human platelet monoamine oxidase activity in iron-deficiency anaemia. Clin Sci Mol Med (1975) 0.88
In vivo cation transport during short-term and long-term digoxin therapy. Br J Clin Pharmacol (1986) 0.87
Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378. Eur J Pharmacol (1990) 0.87
A sensitive high-temperature electrothermal atomic absorption analysis for Rb+ in erythrocytes and plasma of normal and hypertensive persons. Clin Chem (1985) 0.87
The effect of chronic antidepressant administration on beta-adrenoceptor function of the rat pineal. Br J Pharmacol (1983) 0.87
Release of endogenous 5-hydroxytryptamine in rat ventral hippocampus evoked by electrical stimulation of the dorsal raphe nucleus as detected by microdialysis: sensitivity to tetrodotoxin, calcium and calcium antagonists. Neuroscience (1990) 0.86
Penetration of C14-labelled rifampicin into primate peripheral nerve. Experientia (1975) 0.86
Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex. J Neurochem (1989) 0.85
Unchanged rate of brain serotonin synthesis during chronic morphine treatment and failure of parachlorophenylalanine to attenuate withdrawal syndrome in mice. Nature (1970) 0.85
Bioavailability of digoxin. Lancet (1972) 0.85
5-HT1A and 5-HT2 receptors differentially regulate the excitability of 5-HT-containing neurones of the guinea pig dorsal raphe nucleus in vitro. Brain Res (2001) 0.84
Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' own erythrocytes during glycoside therapy. Klin Wochenschr (1981) 0.84
Neuroendocrine effects of azapirones. J Clin Psychopharmacol (1990) 0.84
5-HT3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. Eur J Pharmacol (1993) 0.84
Academic pursuits in clinical pharmacology. Research emphasis. Clin Pharmacol Ther (1986) 0.84
Repeated administration of subconvulsant doses of GABA antagonist drugs. I. Effect on seizure threshold (kindling). Psychopharmacology (Berl) (1982) 0.84
Influence of thyroid hormone on 5-HT(1A) and 5-HT(2A) receptor-mediated regulation of hippocampal BDNF mRNA expression. Neuropharmacology (2001) 0.83
Localization of 5-HT3 receptor binding sites in human dorsal vagal complex. Eur J Pharmacol (1989) 0.83
Inhibition of adenyl cyclase by an exotoxin of Bacillus thuringiensis. Nature (1975) 0.83
The effect of lithium on 5-HT-mediated neuroendocrine responses and platelet 5-HT receptors. Psychopharmacology (Berl) (1986) 0.83
Bioavailability of digoxin. Lancet (1972) 0.82
Serotonergic regulation of mRNA expression of Arc, an immediate early gene selectively localized at neuronal dendrites. Neuropharmacology (2000) 0.82
Clinical pharmacology. Adverse drug interactions. Br Med J (Clin Res Ed) (1981) 0.82
Action of adenosine receptor antagonists on hypoxia-induced effects in the rat hippocampus in vitro. Br J Pharmacol (1995) 0.82